Novartis Doubles Up In Optogenetics With Arctos Buy
Complements Acquisition Of Vedere Last Year
Executive Summary
The Basel-based major has swooped to buy fellow Swiss group Arctos in the belief that optogenetics is a promising therapeutic approach that might restore sight to patients who are legally blind.
You may also be interested in...
Adverum Faces Rocky Road As It Switches Gears From DME To Wet AMD
Adverum said it would cease developing ADVM-022 for DME and focus on wet AMD, but the adverse events that prompted the shift could invite further scrutiny in an already competitive market.
GenSight CEO Sees Bright Future After Therapy Gave Blind Man Partial Sight
French biotech GenSight will prioritize its optogenetic GS030 treatment after the combination showed breakthrough results in a form of blindness, its CEO tells Scrip.
Novartis CEO: Oncology Treatment Almost Back To Pre-COVID Levels
The Swiss major's oncology business performed well in the third quarter with Kisqali sales catching the eye despite the specific problems that the pandemic has brought for breast cancer patients.